Drugs A-Z Is my price fair? Price changes Drug markups Drug shortages Recalls Medicare prices Upcoming generics What people paid Guides Share what you paid
Theme

Generic drug

Abacavir price, strengths & recalls

Pharmacies pay $16.57 for 30 tablets of Abacavir 300 mg tablet this week. 12 manufacturers make it. It has 1 recall on record, none ongoing. Its official label last changed on March 18, 2026.

Generic
Pharmacies pay$16.57for 30 tablets of 300 mg tablet+1.2% in 4 weeks
Fair cash price
$29.56
Strengths
1
Makers
12
Updated
Nov 11

Abacavir price by strength

What pharmacies pay for each strength and form this week (Nov 11, 2026), for 30 tablets. Choose one for its fair price, 52-week chart and makers.

Strength and formPer unitPharmacies pay4 weeks52 weeks
20 mg/mL oral solutionNot priced this week
300 mg tablet$0.5523$16.57 / 30 tablets+1.2%-14.4%

Supply status: shortages & recalls

No shortage reportedChecked Nov 16, 2026
No ongoing recalls1 recall on record, latest Jul 18, 2012

Recalls

A recall names specific lots. Check the lot number on your package against the recall before you worry - and don't stop a medicine without asking your pharmacist. What to do if your medication is recalled.

What did you pay for abacavir? Help the next person.

Every price shared helps the next person know what's fair - and shows which pharmacies charge the least. Anonymous, 30 seconds.

How were you treated? optional

Free, anonymous, no sign-up. Please don't include personal or health details. Community rules.

Official label & what changed

Last changedMarch 18, 2026
Version6 of 6
EffectiveMar 5, 2026
Read the label

These highlights do not include all the information needed to use ABACAVIR TABLETS safely and effectively. See full prescribing information for ABACAVIR TABLETS. ABACAVIR tablets, for oral use Initial U.S. Approval: 1998

This drug has a boxed warning

WARNING: HYPERSENSITIVITY REACTIONS

Serious and sometimes fatal hypersensitivity reactions, with multiple organ involvement, have occurred with abacavir.

Patients who carry the HLA-B*5701 allele are at a higher risk of a hypersensitivity reaction to abacavir; although, hypersensitivity reactions have occurred in patients who do not carry the HLA-B*5701 allele [see Warnings and Precautions (5.1)].

Abacavir is contraindicated in patients with a prior hypersensitivity reaction to abacavir and in HLA-B*5701-positive patients [see Contraindications (4), Warnings and Precautions (5.1)]. All patients should be screened for the HLA-B*5701 allele prior to initiating therapy with abacavir or reinitiation of therapy with abacavir, unless patients have a previously documented HLA-B*5701 allele assessment. Discontinue abacavir immediately if a hypersensitivity reaction is suspected, regardless of HLA-B*5701 status and even when other diagnoses are possible [see Contraindications (4), Warnings and Precautions (5.1)].

Following a hypersensitivity reaction to abacavir, NEVER restart abacavir or any other abacavir-containing product because more severe symptoms, including death can occur within hours. Similar severe reactions have also occurred rarely following the reintroduction of abacavir-containing products in patients who have no history of abacavir hypersensitivity [see Warnings and Precautions (5.1)].

WARNING: HYPERSENSITIVITY REACTIONS

See full prescribing information for complete boxed warning.

•

Serious and sometimes fatal hypersensitivity reactions have occurred with abacavir. (5.1)

•

Hypersensitivity to abacavir is a multi-organ clinical syndrome. (5.1)

•

Patients who carry the HLA-B*5701 allele are at a higher risk of experiencing a hypersensitivity reaction to abacavir. (5.1)

•

Abacavir is contraindicated in patients with a prior hypersensitivity reaction to abacavir and in HLA-B*5701-positive patients. (4)

•

Discontinue abacavir as soon as a hypersensitivity reaction is suspected. Regardless of HLA-B*5701 status, permanently discontinue abacavir if hypersensitivity cannot be ruled out, even when other diagnoses are possible. (5.1)

•

Following a hypersensitivity reaction to abacavir, NEVER restart abacavir or any other abacavir-containing product. (5.1)

We check this label every day. When it changes, the sections that changed appear here, old text beside new.

We show the official text and what changed; we don't interpret it. Ask your pharmacist or prescriber what a change means for you.

Approval, patents & generics

Generic makers
6 approved generic applications on the market

Abacavir questions

How much does abacavir cost without insurance?

Pharmacies pay about $16.57 for 30 tablets of abacavir 300 mg tablet ($0.5523 per tablet). A fair cash price - that cost plus a 15% margin and a typical dispensing fee - is about $29.56. If you're quoted much more, check your quote and ask for the pharmacy's cash price.

Is abacavir in shortage?

No shortage is reported for abacavir right now. We check the national shortage list every day.

Has abacavir been recalled?

1 recall on record, none ongoing. Recalls name specific lots - check yours.

When did the abacavir label last change?

The official label was last updated on March 18, 2026 (version 6). See what changed.

Talk about abacavir

Be kind and stay on topic. No personal health details, links or selling. This is not medical advice.

No comments yet. Questions, tips, what worked for you - start the conversation.

Help the next person

Know what your pharmacy pays.

Every price you share shows someone else what's fair - and which pharmacies charge the least. It takes 30 seconds and it's anonymous.